Humex Toux Seche (Oxomemazine)

Humex Toux Seche is generally used to alleviate cough symptoms that are not productive and are linked to allergic or upper‑respiratory tract conditions.

• Dry (non‑productive) cough, providing symptomatic suppression of the cough reflex.
• Cough accompanying common cold or other upper respiratory tract infections.
• Allergy‑related cough triggered by histamine‑mediated airway irritation.
• Irritative cough caused by throat dryness or exposure to smoke or pollutants.
• Night‑time cough that disturbs sleep, used as part of a short‑term regimen.
• Cough associated with mild allergic rhinitis when other antihistamines are not suitable.

• Oxomemazine acts primarily as an antagonist at peripheral and central histamine H1 receptors. By blocking H1 receptors in the central nervous system, it reduces the sensitivity of the cough centre in the medulla, leading to suppression of the cough reflex. The drug also exhibits anticholinergic activity, which may contribute to drying of secretions in the respiratory tract, further decreasing cough stimulation.

Oxomemazine may cause a range of adverse effects; most are mild and transient, while rare reactions can be more serious and may require medical attention.

Common

• Drowsiness or sedation, which may impair alertness and affect activities such as driving.
• Dry mouth or throat, leading to discomfort and a feeling of increased thirst.
• Dizziness or light‑headedness, especially when standing quickly or after prolonged sitting.
• Constipation or reduced bowel movements, occasionally accompanied by abdominal discomfort.

Serious

• Allergic skin reactions such as rash, urticaria, or angio‑edema that may spread or involve the face.
• Cardiac arrhythmias or tachycardia, which can present as palpitations and require medical evaluation.
• Severe hypotension that can cause fainting, dizziness, or shock in extreme cases.
• Extrapyramidal symptoms (rare), including muscle rigidity, tremor, or involuntary movements.

When considering Humex Toux Seche, certain precautions should be observed to minimize risk and ensure safe use.

• Avoid use in patients with known hypersensitivity to oxomemazine or other first‑generation antihistamines.
• Use caution in individuals with asthma, chronic obstructive pulmonary disease, or other respiratory disorders, as cough suppression may mask underlying conditions.
• Consider the sedative potential in patients who operate machinery, drive, or require mental alertness.
• Use with care in the elderly, who may be more susceptible to anticholinergic effects such as confusion or urinary retention.
• Assess liver or kidney impairment before use, as metabolism and excretion may be altered.
• Pregnant or breastfeeding women should consult a healthcare professional before taking the product.

Oxomemazine can interact with other medicines; awareness of potential interactions helps prevent adverse outcomes.

Avoid

• Concomitant use with other central nervous system depressants (e.g., benzodiazepines, opioids, alcohol) that may intensify sedation.
• Combination with monoamine oxidase inhibitors (MAOIs) or other antihistamines, increasing anticholinergic burden.

Use with caution

• Concurrent administration of drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Use with other anticholinergic agents (e.g., tricyclic antidepressants, antipsychotics) may enhance dry‑mouth or urinary retention.
• Caution when combined with hepatic enzyme inhibitors (e.g., erythromycin, cimetidine) that could affect oxomemazine metabolism.
• When taken with medications that affect renal clearance, dose adjustment may be necessary.